Skip to content
Blerp – Lifestyle
Author:
Oblenio Bio, Inc.
Oblenio Bio Closes $62 Million Series B to Advance Tri-specific T-Cell Engager LBL-051 for Autoimmune Diseases into Clinical Development
June 25, 2026